Derma Sciences has reported net sales of $15.88m for the second quarter ended 30 June 2011, an increase of 20% compared to $13.23m for the same period in 2010.
Advanced wound care product sales of $3.8m increased 47% from the prior year with Medihoney sales up 66%.
Derma Sciences’ net loss was $551,295, or $0.07 loss per diluted share, compared to net loss of $976,640 or $0.15 loss per diluted share for the same period in the prior year.
The company’s operating loss was $469,073 for the second quarter ended 30 June 2011, compared to $785,614 for the same period in 2010.
For the six months ended 30 June 2011 net sales were $30.25m, compared to $26.07m for the same period in 2010.
Net loss was $2m for the six months ended 30 June 2011, compared to $1.56m for the same period prior year.
For the six months ended 30 June 2011, the company’s operating loss was $922,537, compared to $2m for the same period in 2010.
Derma Sciences chairman and CEO Edward Quilty said they are optimistic that Medihoney sales will continue on a growth trajectory, and note that for the first time the prior-year comparison includes a full quarter of sales in Europe following the licensing of global rights to Medihoney in February 2010.